Krzysztof Bujko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Krzysztof Bujko has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Anna Hołdakowska
Department of Radiology, M. Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
2 shared publicationsJoanna Socha
Department of Radiotherapy, Military Institute of Medicine, Warsaw, Poland; Department of Radiotherapy, Regional Oncology Center, Czestochowa, Poland
2 shared publicationsAgnieszka Zółciak-Siwińska
Department of Gynecological Oncology, M. Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
1 shared publicationAndrzej Rutkowski
Department of Gastroenterological Oncology, M. Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
1 shared publicationAnna Cencelewicz
Department of Gastroenterological Oncology, M. Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
1 shared publicationIwona Gisterek
Department of Radiotherapy, Nu-Med Group, Zamość, Poland
1 shared publication
Latest Publications
- Open Access
Does the Gain of Total Neoadjuvant Therapy Outweigh the Harm in Rectal Cancer? Importance of the ATRESS (neoAdjuvant Therapy-RElated Shortening of Survival) Phenomenon: A Systematic Review
Background: We aimed to evaluate whether total neoadjuvant therapy (TNT) results in long-term overall survival (OS) or quality of life (QoL) benefit compared with chemoradiation if all patients are being considered for radical resection, and whether the ATRESS phenomenon (i.e., reduction in post-metastatic survival) impacts OS after TNT. Methods: Systematic review of randomised trials comparing TNT with neoadjuvant (chemo)radiation. Results: Six trials were identified. Follow-ups were too short to resolve whether TNT improves long-term OS. QoL analysis in one trial showed worse long-term neurotoxicity-related QoL (any neurotoxicity: 14% vs. 3%), higher rate of grade III+ acute toxicity (48% vs. 25%), longer duration of neoadjuvant treatment (19 vs. 6 weeks) and higher rate of locoregional failure (10% vs. 7%) in TNT vs. chemoradiation. This should be weighed against an absolute 8% reduction in the incidence of distant metastases (DM) after TNT. ATRESS could explain a discrepancy between reduction of DM and the absence of OS improvement after TNT in one trial. Conclusion: In the light of unproven OS benefit, the gain of TNT (reduction of DM) does not seem to outweigh the harm (excess of toxicity). ATRESS can be a reason for the absence of the OS benefit despite the reduction in DM.
Open AccessDoes the Gain of Total Neoadjuvant Therapy Outweigh the Harm in Rectal Cancer? Importance of the ATRESS (neoAdjuvant Therapy-RElated Shortening of Survival) Phenomenon: A Systematic Review
Background: We aimed to evaluate whether total neoadjuvant therapy (TNT) results in long-term overall survival (OS) or quality of life (QoL) benefit compared with chemoradiation if all patients are being considered for radical resection, and whether the ATRESS phenomenon (i.e., reduction in post-metastatic survival) impacts OS after TNT. Methods: Systematic review of randomised trials comparing TNT with neoadjuvant (chemo)radiation. Results: Six trials were identified. Follow-ups were too short to resolve whether TNT improves long-term OS. QoL analysis in one trial showed worse long-term neurotoxicity-related QoL (any neurotoxicity: 14% vs. 3%), higher rate of grade III+ acute toxicity (48% vs. 25%), longer duration of neoadjuvant treatment (19 vs. 6 weeks) and higher rate of locoregional failure (10% vs. 7%) in TNT vs. chemoradiation. This should be weighed against an absolute 8% reduction in the incidence of distant metastases (DM) after TNT. ATRESS could explain a discrepancy between reduction of DM and the absence of OS improvement after TNT in one trial. Conclusion: In the light of unproven OS benefit, the gain of TNT (reduction of DM) does not seem to outweigh the harm (excess of toxicity). ATRESS can be a reason for the absence of the OS benefit despite the reduction in DM.
- Open Access
- 17 November 2022
- Published by Elsevier in The Lancet Healthy Longevity
- Vol. 3 (12) , e807-e808
A watch-and-wait strategy or local excision in complete clinical responders after radiation for early-stage rectal cancer
- 17 November 2022
- Published by Elsevier in The Lancet Healthy Longevity
- Vol. 3 (12) , e807-e808
Open AccessA watch-and-wait strategy or local excision in complete clinical responders after radiation for early-stage rectal cancer
- 2 September 2022
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (9) , 1121-1125
The utility of short-course radiotherapy in a watch-and-wait strategy for rectal cancer – the need to measure the interval to tumour response assessment from the radiation start
The watch-and-wait strategy (w&w) is gaining momentum in rectal cancer [1–8]. Most of the w&w observations come from reports showing the outcomes after neoadjuvant long-course chemoradiation (CRT) ...
- 2 September 2022
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (9) , 1121-1125
The utility of short-course radiotherapy in a watch-and-wait strategy for rectal cancer – the need to measure the interval to tumour response assessment from the radiation start
The watch-and-wait strategy (w&w) is gaining momentum in rectal cancer [1–8]. Most of the w&w observations come from reports showing the outcomes after neoadjuvant long-course chemoradiation (CRT) ...
- 2 September 2022
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (9) , 1084-1092
The importance of measuring baseline tumour volume (or alternatively tumour length along with its rectal circumferential extent) in the watch-and-wait strategy in rectal cancer: a review
The impact of the tumour volume or size on achieving clinical complete response (cCR) after radio(chemo)therapy is poorly understood.A literature search was performed to gather data on the predicti...
- 2 September 2022
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (9) , 1084-1092
The importance of measuring baseline tumour volume (or alternatively tumour length along with its rectal circumferential extent) in the watch-and-wait strategy in rectal cancer: a review
The impact of the tumour volume or size on achieving clinical complete response (cCR) after radio(chemo)therapy is poorly understood.A literature search was performed to gather data on the predicti...